NCT00726674

Completed

Basal Insulin for Type 2 Diabetes Patients Treated in Outpat...

Sanofi Source

Compare

Other study identifiers

Sponsor study identifier

LANTU_L_04137

Study Type

observational

Actual enrollment (reported)

1,229

Locations

1 country

Sites

1

Timeline

Study Start

August 2008

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

January 2012

Actual (reported)

Study Completion

January 2012

Actual (reported)

Brief Summary

Treatment of diabetes mellitus type II with basal insulin, for patients treated in Clalit outpatient clinics that are not adequately controlled with current treatment.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 1,229 participants
Study completion date: January 2012
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

First Submitted
July 30, 2008
Actual (reported)
Study Start
August 2008
Date type not reported
This date has not been verified as actual or estimated.
First Posted
August 1, 2008
Actual (reported)
Primary Completion
January 2012
Actual (reported)
Study Completion
January 2012
Actual (reported)

Last Updated: March 8, 2012
Status Verified: March 2012
Last Update Submitted: March 7, 2012

Conditions

Type 2 Diabetes

Keywords

Diabetes HbA1C

Outcome Measures

Primary Outcomes (1)

Decrease in HbA1c level
6 months

Secondary Outcomes (1)

Safety measures
7 months

Eligibility Criteria

Age21 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Type II diabetes.

You may qualify if:

Type II Diabetic patients

Sponsors & Collaborators

Sanofi
Industrylead

Study Sites (1)

Sanofi-Aventis Administrative Office

Netanya, Israel

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Officials

Nurit Tweezer-Zaks
Sanofi
STUDY DIRECTOR

Enrollment

1,229 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: INDUSTRY
Responsible Party: SPONSOR

Study Record Dates

First Submitted

July 30, 2008

First Posted

August 1, 2008

Study Start

August 2008

Date type not reported

This date has not been verified as actual or estimated.

NCT00715624

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin

Phase 3Completed

NCT00693771

Study to Optimize Insulin Treatment by Basal Regimen With Insulin Glargine in Type-2-Diabetic Patients Previously Uncontrolled on Premixed Insulin

Phase 4Completed

NCT00941369

Health Assessment, Patient Treatment Satisfaction and Quality-of-Life in Insulin-Naive Type 2 Diabetes Patients

Phase 4Completed

NCT00866658

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)

Phase 3Completed

NCT00965549

Comparison of a Basal Plus One Insulin Regimen With a Biphasic Insulin Regimen in Type 2 Diabetes Patients

Phase 4Completed

NCT00627471

Type 2 Diabetes Management With Lantus® (Malbec: Manejo Con Lantus® de Diabéticos Tipo 2)

Phase 4Terminated

HbA1c \>8.0% (result from preceding 4 months)

Written informed consent

Life expectancy of at least 1 year.

Patients' agree to discontinue current long acting insulin (if applicable).

Patients who according to their GP are eligible to the study.

You may not qualify if:

Type I diabetes
Pregnancy and\\or lactation.
Allergy to basal insulin
Patients suffering from a disease that requires repeated hospitalizations E.g.: severe CHF, sever renal failure, active malignancy.
Patients who are not able to give consent.
Patients face difficulties in mobility and/or verbal communication with the treating physician.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Contact the study team to confirm eligibility.

Primary Completion

January 2012

Actual (reported)

Study Completion

January 2012

Actual (reported)

Last Updated

March 8, 2012

Record last verified: 2012-03

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00726674
Data provider: ClinicalTrials.gov
Source updated: 2012-03-08
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:23:54 UTC

Locations

IL(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

Study Start

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations